SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-011701
Filing Date
2021-08-13
Accepted
2021-08-13 17:01:36
Documents
78
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20210630x10q.htm   iXBRL 10-Q 1726772
2 EX-31.1 otlk-20210630xex31d1.htm EX-31.1 9498
3 EX-31.2 otlk-20210630xex31d2.htm EX-31.2 11995
4 EX-32.1 otlk-20210630xex32d1.htm EX-32.1 9494
  Complete submission text file 0001558370-21-011701.txt   7824510

Data Files

Seq Description Document Type Size
5 EX-101.SCH otlk-20210630.xsd EX-101.SCH 56757
6 EX-101.CAL otlk-20210630_cal.xml EX-101.CAL 58683
7 EX-101.DEF otlk-20210630_def.xml EX-101.DEF 246711
8 EX-101.LAB otlk-20210630_lab.xml EX-101.LAB 453109
9 EX-101.PRE otlk-20210630_pre.xml EX-101.PRE 432271
10 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20210630x10q_htm.xml XML 1390635
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 211173193
SIC: 2836 Biological Products, (No Diagnostic Substances)